Inhibitory effects of obovatol on osteoclast differentiation and bone resorption

European Journal of Pharmacology

Volumn 723, Issue 1, 2014, Pages 473-480

  Kim, Hyun Ju ^a   Hong, Jung Min ^a   Yoon, Hye Jin ^a   Kwon, Byoung Mog ^b   Choi, Je Yong ^c   Lee, In Kyu ^c   Kim, Shin Yoon ^a,c  

^a Kyungpook National University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c Kyungpook National University School of Medicine   (South Korea)

Author keywords

Apoptosis; Bone resorption; Cytoskeletal organization; Obovatol; Osteoclast; RANKL

Indexed keywords

APOPTOSIS; BONE RESORPTION; CYTOSKELETAL ORGANIZATION; OBOVATOL; OSTEOCLAST; RANKL;

ANIMALS; BIPHENYL COMPOUNDS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CASPASE 3; CELL DIFFERENTIATION; FEMUR; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; PHENYL ETHERS; PROTO-ONCOGENE PROTEINS C-FOS; RANK LIGAND;

EID: 84893756178     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.10.027     Document Type: Article

References (43)

1. D.M. Anderson, E. Maraskovsky, W.L. Billingsley, W.C. Dougall, M.E. Tometsko, E.R. Roux, M.C. Teepe, R.F. DuBose, D. Cosman, and L. Galibert A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function Nature 390 1997 175 179 (Pubitemid 27507987)
2. M. Asagiri, and H. Takayanagi The molecular understanding of osteoclast differentiation Bone 40 2007 251 264 (Pubitemid 46054562)
3. R. Baron, and E. Hesse Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives J. Clin. Endocrinol. Metab. 97 2012 311 325
4. M.L. Bouxsein, S.K. Boyd, B.A. Christiansen, R.E. Guldberg, K.J. Jepsen, and R. Muller Guidelines for assessment of bone microstructure in rodents using micro-computed tomography J. Bone Mineral Res. 25 2010 1468 1486
5. W.J. Boyle, W.S. Simonet, and D.L. Lacey Osteoclast differentiation and activation Nature 423 2003 337 342 (Pubitemid 40852708)
6. A. Bruzzaniti, and R. Baron Molecular regulation of osteoclast activity Rev. Endocr. Metab. Disord. 7 2006 123 139 (Pubitemid 46044352)
7. L. Chang, and M. Karin Mammalian MAP kinase signalling cascades Nature 410 2001 37 40 (Pubitemid 32225829)
8. D.Y. Choi, J.W. Lee, J. Peng, Y.J. Lee, J.Y. Han, Y.H. Lee, I.S. Choi, S.B. Han, J.K. Jung, W.S. Lee, S.H. Lee, B.M. Kwon, K.W. Oh, and J.T. Hong Obovatol improves cognitive functions in animal models for Alzheimer's disease J. Neurochem. 120 2012 1048 1059
9. D.Y. Choi, Y.J. Lee, S.Y. Lee, Y.M. Lee, H.H. Lee, I.S. Choi, K.W. Oh, S.B. Han, S.Y. Nam, and J.T. Hong Attenuation of scopolamine-induced cognitive dysfunction by obovatol Arch. Pharmacal Res. 35 2012 1279 1286
10. M.S. Choi, S.H. Lee, H.S. Cho, Y. Kim, Y.P. Yun, H.Y. Jung, J.K. Jung, B.C. Lee, H.B. Pyo, and J.T. Hong Inhibitory effect of obovatol on nitric oxide production and activation of NF-kappaB/MAP kinases in lipopolysaccharide-treated RAW 264.7cells Eur. J. Pharmacol. 556 2007 181 189 (Pubitemid 46098933)
11. R. Faccio, W. Zou, G. Colaianni, S.L. Teitelbaum, and F.P. Ross High dose M-CSF partially rescues the Dap12-/- osteoclast phenotype J. Cell. Biochem. 90 2003 871 883 (Pubitemid 37467103)
12. G. Franzoso, L. Carlson, L. Xing, L. Poljak, E.W. Shores, K.D. Brown, A. Leonardi, T. Tran, B.F. Boyce, and U. Siebenlist Requirement for NF-kappaB in osteoclast and B-cell development Genes Dev. 11 1997 3482 3496 (Pubitemid 28023969)
13. A.E. Grigoriadis, Z.Q. Wang, M.G. Cecchini, W. Hofstetter, R. Felix, H.A. Fleisch, and E.F. Wagner c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling Science 266 1994 443 448
14. H. Hirotani, N.A. Tuohy, J.T. Woo, P.H. Stern, and N.A. Clipstone The calcineurin/nuclear factor of activated T cells signaling pathway regulates osteoclastogenesis in RAW264.7 cells J. Biol. Chem. 279 2004 13984 13992 (Pubitemid 38468932)
15. J.M. Hong, S.L. Teitelbaum, T.H. Kim, F.P. Ross, S.Y. Kim, and H.J. Kim Calpain-6, a target molecule of glucocorticoids, regulates osteoclastic bone resorption via cytoskeletal organization and microtubule acetylation J. Bone Miner. Res. 26 2011 657 665
16. V. Iotsova, J. Caamano, J. Loy, Y. Yang, A. Lewin, and R. Bravo Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2 Nat. Med. 3 1997 1285 1289 (Pubitemid 27508833)
17. A. Ishida, N. Fujita, R. Kitazawa, and T. Tsuruo Transforming growth factor-beta induces expression of receptor activator of NF-kappa B ligand in vascular endothelial cells derived from bone J. Biol. Chem. 277 2002 26217 26224 (Pubitemid 34967109)
18. R.S. Johnson, B.M. Spiegelman, and V. Papaioannou Pleiotropic effects of a null mutation in the c-fos proto-oncogene Cell 71 1992 577 586
19. H.J. Kim, J.M. Hong, K.A. Yoon, N. Kim, D.W. Cho, J.Y. Choi, I.K. Lee, and S.Y. Kim Early growth response 2 negatively modulates osteoclast differentiation through upregulation of Id helix-loop-helix proteins Bone 51 2012 643 650
20. H.J. Kim, H. Zhao, H. Kitaura, S. Bhattacharyya, J.A. Brewer, L.J. Muglia, F.P. Ross, and S.L. Teitelbaum Glucocorticoids suppress bone formation via the osteoclast J. Clin. Invest. 116 2006 2152 2160 (Pubitemid 44162324)
21. D.L. Lacey, E. Timms, H.L. Tan, M.J. Kelley, C.R. Dunstan, T. Burgess, R. Elliott, A. Colombero, G. Elliott, S. Scully, H. Hsu, J. Sullivan, N. Hawkins, E. Davy, C. Capparelli, A. Eli, Y.X. Qian, S. Kaufman, I. Sarosi, V. Shalhoub, G. Senaldi, J. Guo, J. Delaney, and W.J. Boyle Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 93 1998 165 176 (Pubitemid 28180851)
22. M. Lee, B.M. Kwon, K. Suk, E. McGeer, and P.L. McGeer Effects of obovatol on GSH depleted glia-mediated neurotoxicity and oxidative damage J. Neuroimmunol. Pharmacol. 7 2012 173 186
23. S.K. Lee, H.N. Kim, Y.R. Kang, C.W. Lee, H.M. Kim, D.C. Han, J. Shin, K. Bae, and B.M. Kwon Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis Bioorg. Med. Chem. 16 2008 8397 8402
24. S.Y. Lee, D.Y. Yuk, H.S. Song, Y. Yoondo, J.K. Jung, D.C. Moon, B.S. Lee, and J.T. Hong Growth inhibitory effects of obovatol through induction of apoptotic cell death in prostate and colon cancer by blocking of NF-kappaB Eur. J. Pharmacol. 582 2008 17 25
25. Y.J. Lee, Y.M. Lee, C.K. Lee, J.K. Jung, S.B. Han, and J.T. Hong Therapeutic applications of compounds in the Magnolia family Pharmacol. Ther. 130 2011 157 176
26. T.J. Martin, and N.A. Sims Osteoclast-derived activity in the coupling of bone formation to resorption Trends Mol. Med. 11 2005 76 81 (Pubitemid 40193486)
27. K.P. McHugh, K. Hodivala-Dilke, M.H. Zheng, N. Namba, J. Lam, D. Novack, X. Feng, F.P. Ross, R.O. Hynes, and S.L. Teitelbaum Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts J. Clin. Invest. 105 2000 433 440 (Pubitemid 30127243)
28. T. Nakashima, and H. Takayanagi New regulation mechanisms of osteoclast differentiation Ann. N.Y. Acad. Sci. 1240 2011 E13 18
29. D.V. Novack, and S.L. Teitelbaum The osteoclast: friend or foe? Annu. Rev. Pathol. 3 2008 457 484 (Pubitemid 351488289)
30. J. Ock, H.S. Han, S.H. Hong, S.Y. Lee, Y.M. Han, B.M. Kwon, and K. Suk Obovatol attenuates microglia-mediated neuroinflammation by modulating redox regulation Br. J. Pharmacol. 159 2010 1646 1662
31. E.S. Park, Y. Lim, S.H. Lee, B.M. Kwon, H.S. Yoo, J.T. Hong, and Y.P. Yun Antiplatelet activity of obovatol, a biphenolic component of Magnolia Obovata, in rat arterial thrombosis and rabbit platelet aggregation J. Atheroscler. Thromb. 18 2011 659 669
32. M.K. Pyo, Y. Lee, and H.S. Yun-Choi Anti-platelet effect of the constituents isolated from the barks and fruits of Magnolia obovata Arch. Pharmacal. Res. 25 2002 325 328
33. M.G. Ruocco, S. Maeda, J.M. Park, T. Lawrence, L.C. Hsu, Y. Cao, G. Schett, E.F. Wagner, and M. Karin I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss J. Exp. Med. 201 2005 1677 1687 (Pubitemid 40721011)
34. H. Takayanagi, S. Kim, T. Koga, H. Nishina, M. Isshiki, H. Yoshida, A. Saiura, M. Isobe, T. Yokochi, J. Inoue, E.F. Wagner, T.W. Mak, T. Kodama, and T. Taniguchi Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts Dev. Cell 3 2002 889 901 (Pubitemid 35460788)
35. S. Tanaka, K. Nakamura, N. Takahasi, and T. Suda Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system Immunol. Rev. 208 2005 30 49 (Pubitemid 41746383)
36. S.L. Teitelbaum Bone resorption by osteoclasts Science 289 2000 1504 1508
37. S.L. Teitelbaum Osteoclasts: what do they do and how do they do it? Am. J. Pathol. 170 2007 427 435 (Pubitemid 47339379)
38. S.L. Teitelbaum, and F.P. Ross Genetic regulation of osteoclast development and function Nat. Rev. Genet. 4 2003 638 649 (Pubitemid 36917505)
39. E.F. Wagner Bone development and inflammatory disease is regulated by AP-1 (Fos/Jun) Ann. Rheum. Dis. 69 Suppl. 1 2010 i86 88
40. Z.Q. Wang, C. Ovitt, A.E. Grigoriadis, U. Mohle-Steinlein, U. Ruther, and E.F. Wagner Bone and haematopoietic defects in mice lacking c-fos Nature 360 1992 741 745 (Pubitemid 23012271)
41. B.R. Wong, R. Josien, S.Y. Lee, B. Sauter, H.L. Li, R.M. Steinman, and Y. Choi TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor J. Exp. Med. 186 1997 2075 2080 (Pubitemid 28013694)
42. T. Yamashita, Z. Yao, F. Li, Q. Zhang, I.R. Badell, E.M. Schwarz, S. Takeshita, E.F. Wagner, M. Noda, K. Matsuo, L. Xing, and B.F. Boyce NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1 J. Biol. Chem. 282 2007 18245 18253 (Pubitemid 47100255)
43. H. Yasuda, N. Shima, N. Nakagawa, K. Yamaguchi, M. Kinosaki, S. Mochizuki, A. Tomoyasu, K. Yano, M. Goto, A. Murakami, E. Tsuda, T. Morinaga, K. Higashio, N. Udagawa, N. Takahashi, and T. Suda Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL Proc. Nat. Acad. Sci. U.S.A. 95 1998 3597 3602